Neutre
Johnson & Johnson's stock price remains steady at $275.21 amid recent developments.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Over the past 24 hours, Johnson & Johnson's stock price has remained steady at $275.21. Recent developments include the company's participation in the Deutsche Bank 2026 Healthcare Summit on September 17, 2026, and UBS initiating coverage with a 'Buy' rating and a price target of $320, up from $280. Additionally, the company announced a quarterly dividend of $1.34 per share, payable on September 8, 2026.
Points clés
- Johnson & Johnson's stock price remains steady at $275.21.
- Company to participate in the Deutsche Bank 2026 Healthcare Summit on September 17, 2026.
- UBS initiates coverage with a 'Buy' rating and a price target of $320, up from $280.
- Announced a quarterly dividend of $1.34 per share, payable on September 8, 2026.
Sources
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare SummitBusiness Wire · September 3, 2026
- Johnson & Johnson assumed with a Buy at UBSTheFly · September 2, 2026
- Johnson & Johnson stock holds firm after July earnings beatAD HOC NEWS · August 18, 2026
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025Business Wire · October 14, 2025
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
